FFG Austrian Life Sciences
Supports Austrian life-science innovation in digital health, drug development, and medical technologies.
The Austrian Life Sciences 2024–2026 call funds Austrian company-led R&D and clinical studies in life sciences. Eligible focus areas are digitalization with health aspects (diagnostics, telemedicine, medical devices), new drugs and medical devices, and interventional phase I and II clinical studies. Participation along the entire value chain is required; foreign partners may participate depending on the funding instrument.
Funding caps are 3 m EUR for experimental development (TRL 5–8) and clinical studies (TRL 2–4), and 1 m EUR for industrial research, as non-repayable grants. The 2024–2026 initiative has a total programme budget of 45 m EUR. The call is open for rolling submission from 22 March 2024 until 18 December 2026, 12:00 local, via eCall, with seven decision-board meetings per year. The flagship project route — which also opens eligibility to universities, universities of applied sciences and non-university research institutions — is not offered in 2026, so the 2026 cohort is company-only. Each company is limited to one project per research category. Companies in difficulty are excluded.
Digitalization with health aspects; new drugs and medical devices; planning and implementation of interventional phase I and II clinical studies.
Sign up free to see the funding breakdown
Sign up free to see the industries in scope
Sign up free to see the full eligibility
Sign up free to see how to apply
Sign up free to see what you submit
Sign up free to see the timeline